Semax is a synthetic fragment of ACTH(4-10) with the addition of a Pro-Gly-Pro tail, developed in Russia where it is a registered drug for stroke, optic nerve disease and cognitive disorders. It modulates BDNF and NGF expression in animal studies.
Typically administered intranasally. Western clinical data is essentially absent; everything here is informational only.